Republican Congress To Shift Priorities, But Cancer May Get New Opportunities
In Brief: Ortho Biotec gives $1 Million To Fund Fatigue Initiative; Lippman, Pike Honored
NCI Won’t Recognize Wolmark Wile NSABP is Plaintiff In Suit
DCE Advisors Okay Contract Recompetitions For Epidemiology
Chemical Carcinogenesis
FDA Rile Changes Reporting Requirements for Adverse Events
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
- The insinuation that AstroTurf causes GBM has no basis in science
The Philadelphia Inquirer series does disservice to brain tumor community